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Available online 24 August 2016Background: Allogeneic islet transplantation has become a viable option for the treatment of unstable type 1 di-
abetes. However, the donor shortage and the necessity of the immunosuppressive drugs are twomajor issues. To
solve these issues, we performed islet xenotransplantation using encapsulated neonatal porcine islets without
immunosuppressive drugs.
Methods: Two different doses (approximately 5000 IEQ/kg and 10,000 IEQ/kg) of encapsulated neonatal porcine
islets were transplanted twice (total approximately 10,000 IEQ/kg and 20,000 IEQ/kg) into four type 1 diabetic
patients in each group (total 8 patients).
Findings: In the higher dose group, all four patients improved HbA1c. This was maintained at a level of b7% for
N600 days with signiﬁcant reduction of the frequency of unaware hypoglycemic events.
Interpretation: The clinical beneﬁt of islet xenotransplantation with microencapsulation has been shown.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Transplantation has been considered one of the medical miracles
which can cure incurable diseases (Dalal, 2015). On the other hand,
transplantation has been associated with the donor shortage which
leads to organ trafﬁcking and organ tourism (Dalal, 2015). The Istanbul
declaration, supported by World Health Organization, has emphasized
the importance of changing this situation (Dalal, 2015). One of the ulti-
mate solutions for this situation is xenotransplantation. Among the xe-
notransplantation options, islet xenotransplantation usingporcine islets
has been considered to be the closest to the clinical reality (Groth et al.,
1994). In fact, the initial islet xenotransplantation was conducted in 90s
(Groth et al., 1994). Since then several clinical trials of islet xenotrans-
plantation were conducted; however, clear clinical beneﬁts were rarely
shown (Matsumoto et al., 2014; Valdes-Gonzalez et al., 2005;
Valdes-Gonzalez et al., 2010).
The standard therapy for the type 1 diabetes is intensive insulin ther-
apy which can reduce HbA1c. However the drawback is increasing hypo-
glycemic episodes (The Diabetes Control and Complications Trial
Research Group, 1997). Beta-cell replacement therapy including pancreas
and islet transplantation can normalize HbA1c without increasing hypo-
glycemic episodes; however, the donor shortage and the necessity ofry Inc., Naruto 772-8601, Japan.
tsumoto).
. This is an open access article underimmunosuppressant are major issues to apply the treatments widely
(Matsumoto, 2010). To alleviate the donor shortage, islet transplantation
using non-heart beating human donor was conducted (Matsumoto et al.,
2006), and a living donor (Matsumoto et al., 2005), but these approaches
can never solve this issue generally. Islet xenotransplantationmay be one
of the ultimate solutions to solve the shortage of donated organs.
In this study,we conducted islet xenotransplantation using encapsu-
lated neonatal porcine islets without immunosuppressive drugs which
resulted in clinical beneﬁt for unstable type 1 diabetic patients. We be-
lieve this study provides a prologue for xenotransplantation to solve the
shortage of organ donors.
2. Methods
The donor pig herd (Auckland Island pigs; Living Cell Technologies,
Manukau, New Zealand, and Diatranz Otsuka Ltd, Auckland New
Zealand) was maintained in a designated pathogen-free facility and
screened for an extensive panel of infectious agents including porcine
endogenous retrovirus (PERV) (Garkavenko et al., 2004). Newborn pig-
lets from the donor herd were shipped to a cell processing facility
(Auckland, New Zealand). They were anesthetized and bled. The pro-
cured pancreata were then brought into a cell processing room and
digested under goodmanufacturingpractices (GMP) as described previ-
ously (Hillberg et al., 2013). Digested pancreata were cultured using
spinner ﬂasks for 3 days before encapsulation (Hillberg et al., 2013).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sulated using alginate-poly-L-ornithine-alginate (APA) (Hillberg et al.,
2013). APA-encapsulated neonatal porcine islets were cultured for an
additional three weeks. Then APA-encapsulated neonatal porcine islets
were shipped to Argentine using RPMI culture media at cold
temperature.
FromAugust 2011 to July 2012, encapsulated neonatal porcine islets
were transplanted into the peritoneal cavity via a laparoscope (Fig. 1) at
Hospital Interzonal General de Agudos Eva Peron, SanMartin, Provincia
de Buenos Aires. The study protocol (ClinicalTrials.gov Identiﬁer
NCT01739829)was granted ethics approval in Argentina from theMin-
istry of Health, Buenos Aires Province and the local institutional ethics
committee. All patients provided written consent forms to accept this
treatment. Main inclusion criteria for this study are as follows.
1. Adults (males or females) in the age range 18 to 65 years
2. Diagnosis of type 1 diabetes mellitus (DM) (minimum duration of
5 years) in accordance with the American Diabetes Association's
criteria. Patients should have been treated continuously with insulin
since diagnosis.Fig. 1. Encapsulated neonatal porcine islets were transplanted into peritoneal cavity of
type 1 diabetic patient (A). Laparoscopic observation of intra-peritoneal space at the
time of second transplantation (B).3. Patients with established brittle type 1 diabetes mellitus with a well-
documented chronic history of metabolic instability who cannot
achieve acceptable metabolic control (which may include treatment
with the use of a continuous insulin infusion pump) without
experiencing multiple episodes of hypoglycemia, often with
unawareness.
4. Patients should have a hemoglobin A1c (HbA1c) ≥ 7% and ≤15% cal-
culated as the average of the last four consecutive HbA1c readings
during the 8-week baseline run-in period.
5. Plasma C-peptide b 0.3 ng/ml following a glucagon stimulation test.
6. In addition,we put “the difference between the highest and lowest of
the last four consecutive HbA1C reading should be no more than
1.0%.” as inclusion criteria, however; since patients were brittle
type 1 diabetes, this criterionwas not practical. Therefore, for this in-
terim analysis, we did not use this as inclusion criteria.
There were two groups consisting of patients who received either
approximately 5000 islet equivalent (IEQ)/body weight kg twice (total
approximately 10,000 IEQ/kg) (group 1, n = 4) or 10,000IEQ/kg twice
(total approximately 20,000 IEQ/kg) (group 2, n=4). The second trans-
plantation was conducted at approximately 3 months after the ﬁrst
transplantation. At the time of second transplantation, abdominal cavity
was observed via laparoscopy (Fig. 1B) and samples of encapsulated is-
lets were retrieved for histological analysis.
Outcomes of safety were determined from adverse event reports.
PERV provirus and PERV genomic RNA were detected using a PCR-
based method (Wynyard et al., 2014). PERV antibodies were tested on
patient sera (Wynyard et al., 2014).
Outcomes of efﬁcacy were determined from HbA1c, daily insulin
dose (averaged during 2 weeks), and frequency of unaware hypoglyce-
mic events assessed on a regular basis. The regular assessments were
conducted 5 times before the ﬁrst transplantationwithin approximately
2months, at the time of transplantation and 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12,
13, 15, 16, 24, and 29 months after the ﬁrst transplantation.
To assess the function of transplanted encapsulated neonatal por-
cine islets, transplant estimated function (TEF) was used (Caumo et
al., 2011). TEF was calculated as follows:
HbA1c=5:43þ daily insulin requirement per body weight DIRð Þ½ 
− HbA1c=5:43 Pre−transplant baseþ DIR base½ 
The value of HbA1c at the time of the ﬁrst transplantation was used
as HbA1 base. DIR bases were calculated by taking average during two
weeks before the ﬁrst transplantation.
To assess the efﬁcacy of prevention of unaware hypoglycemia, num-
bers of unaware hypoglycemic events per 4 weeks were assessed using
continuous glucose monitoring and diary cards in which any symptoms
of hypoglycemiawere recordedwhen patients noticed. For the baseline,
unaware hypoglycemic events were counted from week−4 to week
−1 before transplantation.
To assess the long-term effect, HbA1c, daily insulin dose, TEF and un-
aware hypoglycemic events were analyzed at N300 days and 600 days.
Oral glucose tolerance tests (OGTTs) were performed in selected pa-
tients (patients 2, 5, 6, 7, and 8) whose fasting blood glucose levels were
b150 mg/dl approximately 15 months after the 1st implantation. Both
long-action insulin (NPH) and short acting insulin (insulin aspart)
were suspended 24 h and 5 h before OGTT, respectively. Fifty grams of
glucose was taken within 10 min and blood glucose levels were mea-
sured before OGTT, at 30, 60, 90 and 120 min.
Retrieved encapsulated islets at the time of the second transplanta-
tion,were stainedwith acridine orange/propidium iodide (AOPI) viabil-
ity staining, and with an Avidin-Biotin method for insulin and glucagon
staining.
Of note, this manuscript was created based on the interim data anal-
ysis and the ﬁnal data analysis is not completed yet.
Table 1
Patient characteristics.
Pt Group Age
(years)
Duration of
T1DM (years)
Sex Body
weight
(kg)
BMI
(kg/m2)
IEQ/kg
(1st)
IEQ/kg
(2nd)
1 1 40 9.0 F 59 23.2 5135 4853
2 1 19 6.0 M 62 19.9 5221 5414
3 1 38 5.1 M 64 21.5 5480 4844
4 1 22 16.1 M 55 17.3 4963 5180
5 2 64 17.4 F 50 22.9 9470 10,357
6 2 36 8.4 M 89 28.1 8866 10,086
7 2 39 29.6 M 81 27.3 8994 9849
8 2 36 21.6 M 91 30.0 8807 9965
257S. Matsumoto et al. / EBioMedicine 12 (2016) 255–2622.1. Statistical Analysis
Differences between two groups and between values of pre-trans-
plantation and post-transplantation were assessed with the use of
paired Student t-test. A p value b 0.05was considered to represent a sig-
niﬁcant difference. The mean value was described as mean ± standard
errors (SE).
3. Results
3.1. Patient Characteristics
Patient characteristics are shown in Table 1. All patients were affect-
ed with type 1 DM for at least 5 years. There were no signiﬁcant differ-
ences between groups 1 and 2 in age, duration of type 1 DM and body
weight. However, group 2 had signiﬁcant high body mass index (BMI)
comparedwith group1 (p b 0.05). Average total amount of transplanted
islets were 10,273± 278 IEQ/kg in group 1 and 19,099 ± 491 IEQ/kg in
group 2.
3.2. Safety Data
There was only one serious adverse event possibly related to the
procedure which was paralytic ileus. This condition was treated with
medication and recovered with no residual effects. There was no severe0
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Fig. 2. Individual averages of pre- (ﬁve time points) and post- (16 time points) transplant HbA1
and 5 out of 8 cases reduced insulin doses (B) and all cases increased TEF (C) signiﬁcantly. *p bhypoglycemiawhichwasdeﬁned as requiring assistance of another per-
son to administer carbohydrates, glucagon, or take other actions.
For all 8 patients PERV DNA and RNA were assessed at approxi-
mately weeks 1, 4 and 12 following the ﬁrst transplantation and
weeks 1, 4, 12, 24, 52 and 104 following the second transplantation
(allowing for some deviation due to patient scheduling and availabili-
ty). No PERV DNA or PERV RNA was found for all time points and all
patients (Morozov et al., in press).
PERV antibodies were also tested at approximately weeks−1, 4 and
12 following theﬁrst transplantation andweeks 4, 12, 24 and 52 follow-
ing the second transplantation (allowing for some deviation due to pa-
tient scheduling and availability). None of the sera tested showed
reactivity against PERV at any time point. Therefore, no PERV transmis-
sionwas detected for any of the eight patients (Morozov et al., in press).3.3. Individual Efﬁcacy Data
To assess the overall efﬁcacy of islet transplantation, averages of
HbA1c, daily insulin dose and TEF were compared before, and after
transplantation in each case (Fig. 2). In group 1, all 4 patients signiﬁcant-
ly improved HbA1c from 9.5 ± 0.5% to 8.4 ± 0.1%, from 7.5 ± 0.2% to
6.4 ± 0.1%, from 10.9 ± 0.4% to 8.7 ± 0.2% and from 9.2 ± 0.2% to
8.1 ± 0.2% in patients 1, 2, 3 and 4 respectively (A), and TEF from
−0.15 ± 0.11 to 0.15 ± 0.02, from−0.02 ± 0.03 to 0.29 ± 0.03, from
0.00 ± 0.07 to 0.60 ± 0.07 and from 0.03 ± 0.04 to 0.27 ± 0.05 in pa-
tients 1, 2, 3 and 4 respectively (C) and two of four patients signiﬁcantly
reduced daily insulin doses from 42.1 ± 1.1 U to 35.9 ± 0.9 U and from
43.5 ± 0.1 U to 36.0 ± 1.1 U in patients 1, and 2 respectively (B). In
group 2, all 4 patients signiﬁcantly improved HbA1c from 8.8 ± 0.2%
to 6.7 ± 0.1%, from 8.3 ± 0.1% to 6.7 ± 0.1%, from 7.8 ± 0.2% to
6.2± 0.2% and from 8.6± 0.1% to 6.8± 0.1% in patients 5, 6, 7 and 8 re-
spectively (A), and TEF from 0.01 ± 0.02 to 0.46 ± 0.03, from−0.01 ±
0.03 to 0.62 ± 0.04, from −0.03 ± 0.03 to 0.57 ± 0.06 and from
−0.03 ± 0.03 to 0.25 ± 0.03 in patients 5, 6, 7 and 8 respectively (C)
and three of four patients signiﬁcantly reduced daily insulin doses
from 22.9 ± 1.2 U to 18.3 ± 1.0 U and from 79.1 ± 1.1 U to 49.1 ±
3.1U and from73.3±2.1 U to 48.0±2.9 U in patients 5, 6 and 7 respec-
tively (B). Thus, in both groups encapsulated neonatal porcine islets
could provide clinical beneﬁts.-0.5
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c, daily insulin dose and TEF in group 1 (●) and group 2 (○). All cases reduced HbA1c (A)
0.05, **p b 0.01.
Table 2
Long-term efﬁcacies.
A. Long-term efﬁcacy N 300 days
Group Time HbA1c (%) Insulin dose (U) TEF
1 Pre-transplant 9.3 ± 1.4 58.6 ± 18.2 −0.03 ± 0.08
N300 days 8.0 ± 1.2 47.3 ± 16.4 0.43 ± 0.23⁎
2 Pre-transplant 8.4 ± 0.4 59.1 ± 25.2 −0.01 ± 0.02
N300 days 6.5 ± 0.2⁎⁎ 43.1 ± 17.1 0.51 ± 0.19⁎
B. Long-term efﬁcacy N 600 days
Group Time HbA1c (%) Insulin dose (U) TEF
1 Pre-transplant 9.3 ± 1.4 58.6 ± 18.2 −0.03 ± 0.08
N600 days 7.7 ± 0.9 51.0 ± 18.3 0.42 ± 0.21⁎
2 Pre-transplant 8.4 ± 0.4 59.1 ± 25.2 −0.01 ± 0.02
N600 days 6.6 ± 0.5⁎ 43.4 ± 14.5 0.48 ± 0.25⁎
⁎⁎ p b 0.001 compared with pre-transplant value.
⁎ p b 0.01 compared with pre-transplant value.
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Fig. 3. Time course of HbA1c (A), daily insulin dose (B) and TEF (C) in group 1 (●) and
group 2 (○) after encapsulated neonatal porcine islet transplantation twice. The second
transplantation was performed after 3 months of the ﬁrst transplantation.
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After the ﬁrst transplantation, HbA1c was gradually decreased from
8.8 ± 0.6% at the time of transplantation to 7.9 ± 0.5% at three months
in group 1 and from 8.2 ± 0.2% at the time of transplantation to 6.6 ±
0.2% at three months in group 2 (Fig. 3A). After the second transplanta-
tion, the levels of HbA1c maintained and the values were 7.5 ± 0.4% in
group 1 and 6.5 ± 0.3 in group 2 at 29 months.
After the ﬁrst transplantation, insulin doses were increased tran-
siently from 62 ± 11 U at the time of transplantation to 66 ± 15 U at
three months in group 1 but decreased from 62 ± 13 U at the time of
transplantation to 39 ± 8 U at three months in group 2 (Fig. 3B). Then
insulin doses were decreased to 48 ± 11 U at 12 months and 50 ±
8 U at 29 months in group 1. The decreased insulin doses were main-
tained at 43± 9 U at 12 months and 44 ± 7 U at 29months in group 2.
Before transplantation, TEF were around zero in both groups (Fig.
3C). After the ﬁrst transplantation TEF increased to 0.12 ± 0.08 in
group 1 and 0.55± 0.10 in group 2 at 3 months. After the second trans-
plantation TEF maintained high levels and the values were 0.47 ± 0.10
in group 1 and 0.49 ± 0.12 in group 2 at 29 months.
3.5. Long-term Functional Efﬁcacy
To assess the long-term effect, averages of HbA1c, daily insulin dose
and TEF were analyzed at N300 days (Table 2A) and N600 days (Table
2B) in both groups. When analyzed, data at N300 days (7 time points
in each patient) (Table 2A), both groups had signiﬁcantly improved
TEF compared with base-line values (6 time points in each patient). In
addition, group 2 had signiﬁcantly improved HbA1c. When analyzed
data at N600 days (2 time points in each patient) (Table 2B), both
groups had still signiﬁcantly improved TEF. In addition, group 2 had
still signiﬁcantly improved HbA1c. Thus, encapsulated neonatal porcine
islets could function N600 days.
3.6. Prevention of Unaware Hypoglycemic Events
The numbers of mild (b4 mmol/L) (Fig. 4, A-1) and serious
(b3 mmol/L) (Fig. 4, A-2) unaware hypoglycemic events were com-
pared between pre-transplant base line and after transplantation. In
both groups, both mild and serious hypoglycemic events were de-
creased, however; only group 2 showed signiﬁcant reductions. Approx-
imately 40% reduction of the number of both mild (pre-transplant:
69.5 ± 21.2/month to post-transplant: 43.6 ± 2.1/month) and serious
(pre-transplant: 43.5 ± 16.7/month to post-transplant: 26.2 ± 1.8/
month) hypoglycemic events was observed in group 2.
3.7. Long Term Effects on Number of Unaware Hypoglycemic Events
To assess the long-term effect on the number of unaware hypoglyce-
mic events, the number at N300 days (Fig. 4, B-1, 2) and 600 days (Fig. 4,
C-1, 2) were analyzed. At N300 days, group 2 signiﬁcantly reduced the
number of bothmild and serious hypoglycemic events (mild: pre-trans-
plant: 69.5 ± 21.2/month to post-transplant: 42.0 ± 2.3/month, seri-
ous: pre-transplant: 43.5 ± 16.7/month to post-transplant: 24.1 ±
2.3/month) (Fig. 4, B-1, 2). At N600 days, none of group signiﬁcantly re-
duced the number of mild hypo glycemic events (Fig. 4, C-1), however;
group 2 signiﬁcantly reduced the number of serious hypoglycemic
events (pre-transplant: 43.5 ± 16.7/month to post-transplant: 16.4 ±
3.2/month) (Fig. 4, C-2). An approximately 50% reduction of the number
serious hypoglycemic events was observed in group 2 at both N300 and
600 days.
3.8. Oral Glucose Tolerance Test
Fasting blood glucose levels were 104, 113, 149, 119 and 97mg/dl in
patients 2, 5, 6, 7 and 8 respectively (Fig. 5). The peaks blood glucose
259S. Matsumoto et al. / EBioMedicine 12 (2016) 255–262levels were 164, 167, 280, 248, and 228 mg/dl at 60, 90, 90, 60 and
60min in patients 2, 5, 6, 7 and 8, respectively. The blood glucose levels
at 120 min were 96, 105, 182, 206 and 210 mg/dl in patients 2, 5, 6, 7
and 8, respectively. Patient 2 showed a normal pattern and patient 5
showed a marginal pattern. Patients 6, 7 and 8 showed diabetic
patterns.
3.9. Histological Study
Representative appearances of the capsules retrieved three months
after the ﬁrst transplant are shown in Fig. 6A–D. Retrieved encapsulated
islets were intact (Fig. 6A) and viable (Fig. 6B). The islets contained in-
sulin (Fig. 6C) and glucagon (Fig. 6D). For comparison encapsulated0
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transplantation (each patient has 19 time points) (□). Averages of mild (b4 mmol/L) (B-1) a
and after N300 days of transplantation (each patient has 8 time points) (□). Averages of mild
transplantation (■) and after N600 days of transplantation (each patient has 2 time points) (□porcine islets before transplantation is also shown (Fig. 6E). Comparing
pre- and post-transplanted encapsulated islets, transplanted capsule
suffered some ﬁbrosis which might be one of the reasons for not
completely reversing diabetes.
4. Discussion
In this study we assessed safety and efﬁcacy of islet xenotransplan-
tation using encapsulated neonatal porcine islets without
immunosuppression.
In terms of safety, there was only one procedure related serious ad-
verse event and it was resolved without residual effects. For the ob-
served period PERV infection was not seen for any of the patients0
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Fig. 5. Glucose proﬁle of oral glucose tolerance tests in patients 2, 5, 6, 7, and 8 at
approximately 1 year after the second transplantation.
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using the same technology (Matsumoto et al., 2014; Wynyard et al.,
2014).
In terms of efﬁcacy, group 2 (10,000 IEQ/kg × 2 transplantation
group) could maintain HbA1c b 7.0% N600 days with signiﬁcant reduc-
tion of serious unaware hypoglycemia. Hence this study was able to
show the clinical beneﬁt by encapsulated porcine islet xenotransplanta-
tion without immunosuppression.
On the other hand, HbA1c could be reduced by meticulous blood
glucose control. To reduce the HbA1c by meticulous blood glucose con-
trol, the doses of insulin need to be increased. However, in our study,
both HbA1c and daily insulin doses were decreased after transplanta-
tion. Increasing TEF after transplantation also reﬂects that the effect of
reducing the HbA1c is theoretically due to implanted islets. In addition,
we put 8 weeks run-in period before transplantation and during the
run-in period the TEF was approximately 0. Therefore meticulous
blood glucose levels cannot explain the effect of both reducing HbA1c
and daily insulin dose after transplantation. Oral glucose tolerance test
in two recipients (2 and 5) at 15 months after the ﬁrst transplantation
also suggested transplanted islets maintained their function.
It has been demonstrated that measurements of C-peptide levels
in peripheral blood is difﬁcult when islets were transplanted into
peritoneal cavity (Matsumoto et al., 2014; Tuch et al., 2009;
Jacobs-Tulleneers-Thevissen et al., 2013). Therefore we applied TEF to
assess the function of transplanted islets because the TEF does not re-
quire C-peptide levels. TEF was proved to be correlated with other
islet function assessment methods including beta-score, C-peptide/glu-
cose ratio, acute insulin response stimulated by Arginine, and SUITO
index (Caumo et al., 2011). Among the assessment methods of islet
function, SUITO index was well evaluated (Takita and Matsumoto,
2012). In cases of allogeneic islet transplantation, it was demonstrated
that high SUITO index (N26), which usually needs multiple islet trans-
plantations, was associated with achieving insulin independence, im-
proving IVGTT proﬁle, reducing hypoglycemic events, and improving
quality of life (QOL) (Takita and Matsumoto, 2012). Middle SUITO
index (10–25), which usually requires only one islet transplantation,
was associated with improving IVGTT proﬁle, reducing hypoglycemic
events and improving QOL even without achieving insulin indepen-
dence (Takita andMatsumoto, 2012). SUITO index 26 and 10 are equiv-
alent to TEF 0.5 and 0.3 respectively (Caumo et al., 2011). Interestingly,
in group 2, after the ﬁrst transplantation TEF exceeded 0.3 and after the
second transplantation the TEF exceeded 0.5 which were similar to the
allogeneic islet transplantation.
Previously we transplanted encapsulated porcine islets into type 1
diabetic patients with 4 different doses (5000 IEQ/kg, 10,000 IEQ/kg,
15,000 IEQ/kg and 20,000 IEQ/kg) (Matsumoto et al., 2014). TEF was
the highest when transplanted 5000 IEQ/kg but the average of the
value was only 0.17 (Matsumoto et al., 2014). We speculated that too
many islet transplantation into abdominal cavity at once caused oxygen
insufﬁciency for each islet which led to cell death. To avoid this, we
transplanted either 5000 IEQ/kg or 10,000 IEQ/kgﬁrst followed by a sec-
ond transplantation after 3 months in this study. Multiple small dose
transplantation might contribute to improve the efﬁcacy.
This study demonstrated signiﬁcant improvement of HbA1c, reduc-
tion of unaware hypoglycemic events with improved TEF; however, the
reduction of insulin doses was marginal. In cases of allogeneic islet
transplantation, it was demonstrated that single islet transplantation
could improve glycemic control but marginally reduced insulin doses
due to necessity of bolus insulin injection associated with meals
(Sassa et al., 2006). In this study, transplanted encapsulated neonatal
porcine islets might not sufﬁciently respond to the meal. Considering
high TEF, which suggests sufﬁcient insulin secretary ability of islets,
this insufﬁciencymight be due to intra-peritoneal transplant site for en-
capsulated islets. In addition, even HbA1c was signiﬁcantly reduced
after transplantation; HbA1c did not reach the normal levels. This
might be also due to intra-peritoneal transplant site because theremight be a lag time between sensing blood glucose levels and delivering
insulin via ascites. Better transplant sites, for example vascularized areas
under skin or omentum pouch might improve this issue.
Another possible cause of marginal effects of transplanted encapsu-
lated islets was ﬁbrosis of capsule after transplantation as indicated in
the histology study. Though, the histology study was not performed
for quantitative analysis. It was demonstrated that microcapsule could
prevent direct contact of neonatal porcine islets by host immune cells,
however, shed xeno-antigens might escape from the capsule (Rayat et
al., 2000; Kobayashi et al., 2006). This shed xeno-antigenmight activate
indirect pathway resulted in recruitment of CD4+ T cells and macro-
phages around themicrocapsule. The recruited CD4+T cellsmight pro-
duce interferon-gamma and interleukin-10 which induced
inﬂammatory reaction. This inﬂammatory reaction could cause the ﬁ-
brosis of microcapsule. Prevention of the indirect pathway might im-
prove this issue.
In addition,maturation of neonatal islets is one of the important fac-
tors for proper insulin secretory ability (Kobayashi et al., 2008). In this
study,we did not assess thematurity of neonatal islets before transplan-
tation, however; we plan to assess thematurity of neonatal islets before
transplantation for the next clinical trial.
Several clinical studies have been reported about encapsulated
human allogeneic islet transplantations (Tuch et al., 2009;
Jacobs-Tulleneers-Thevissen et al., 2013; Basta et al., 2011), however,
insulin independence or signiﬁcant reduction of insulin doses were
rare. The best clinical outcomes were demonstrated by Basta et al.
(2011) which showed 4 patients maintained HbA1c b 8% at 12 months
and 24 months. In our study, the values of HbA1c in group 2 were b7%
N600 days. This suggests that healthy porcine islets could provide better
function compared with human islets which are usually recovered from
deceased donors.
In conclusion, encapsulated neonatal porcine islet xenotransplanta-
tion could maintain HbA1c b 7% with signiﬁcant reduced hypoglycemic
eventswithout immunosuppression N600 days.We believe this study is
the prologue for the clinical xenotransplantation to solve the issue of
donor shortage.
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